Use of a compound targeting liver sinusoidal endothelial cells, isorhamnetin, in the preparation of a medicament for treating liver fibrosis
By targeting hepatic sinusoidal endothelial cells with isorhamnetin, regulating fenestration structure and mitochondrial autophagy flux, and inhibiting cellular senescence, the problem of lack of direct intervention in existing drug treatments for liver fibrosis has been solved, and effective treatment of liver fibrosis has been achieved.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- SAINS NEW MEDICAL COLLEGE OF GUANGXI UNIV OF TRADITIONAL CHINESE MEDICINE
- Filing Date
- 2026-05-20
- Publication Date
- 2026-07-17
AI Technical Summary
Current drug treatments for liver fibrosis lack effective drugs that directly intervene in the fibrosis process. Research on targeting hepatic sinusoidal endothelial cells has mostly focused on complex nanodelivery systems, and the regulatory effects of natural small molecule compounds on hepatic sinusoidal endothelial cell function have not been reported.
Isorhamnetin was used as a compound targeting hepatic sinusoidal endothelial cells. By regulating the fenestration structure of hepatic sinusoidal endothelial cells, mitochondrial autophagy flux, and inhibiting cell senescence, the liver microcirculation was restored and HSC activation signals were blocked, thus preparing a drug for the treatment of liver fibrosis.
Isorhamnetin significantly restores the number of fenestrations in hepatic sinusoidal endothelial cells, improves hepatic microcirculation, regulates metabolic disorders, inhibits cell senescence, enhances the vitality of hepatic sinusoidal endothelial cells, and achieves an anti-hepatic fibrosis effect.
Smart Images
Figure CN122398780A_ABST